Measures that can be self-administered yet similarly inform a clinician’s in-person assessments may mitigate cost and time burdens associated with in-office cognitive screening.Ĭurrently, there are few cognitive assessments readily available to the public for self-administration. Both of these brief screening measures require administration and interpretation by trained health care professionals and provide useful cognitive data to clinicians and researchers. Tools currently most used in assessment for aMCI include the Montreal Cognitive Assessment (MoCA Nasreddine et al., 2005) and Mini-Mental State Examination ( Folstein et al., 1975). aMCI is representative of the cognitive phenotype of prodromal AD ( Chertkow et al., 2013 Dubois & Albert, 2004). Development and refinement of innovative tools to more accurately identify prodromal AD is an important step toward facilitating intervention and furthering research to identify disease-modifying treatments.Īmnestic mild cognitive impairment (aMCI) is defined as a recent onset memory impairment (with or without impairment in other cognitive domains) not of sufficient severity to interfere with instrumental activities of daily living ( Albert et al., 2011). The prodromal stage of AD has been identified as an ideal time point for the implementation of potentially disease-modifying interventions ( Freitas et al., 2013).
Cognitive screening, Diagnostic accuracy, eHealth, Logistic regression, ValidityĮarly detection of Alzheimer’s disease (AD) is important in the facilitation of timely clinical intervention and in moving toward the development of efficacious treatments.
0 kommentar(er)
